Idaho Falls, ID-based radioisotope manufacturer International Isotopes reported a significant increase in revenue for its 2024 fourth quarter and full fiscal year.
Sales revenues for the fourth quarter (end-December 31) increased 24% to $3.9 million, while full-year 2024 sales revenues increased by 13% to $13.9 million, a historical high, International Isotopes reported. The company’s net income in Q4 increased 325% to $245,819. The company cited a surge in demand for its generic sodium iodide I-131, which is primarily used to treat thyroid cancer and its diseases.
For the full year, International Isotopes reported revenues of $13.9 million, an increase of $1.6 million over the prior year, while net income increased to $8,574, up 101% from a loss of $869,016 in the same period last year.
International Isotopes also reported strong sales of its cobalt product sales and noted it remains the only domestic U.S. manufacturer of high activity cobalt-60 sealed-source products.
